{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hemoglobin+Mutations",
    "query": {
      "condition": "Hemoglobin Mutations"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 7,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-05-22T05:37:19.859Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06439082",
      "title": "A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 315,
      "start_date": "2024-10-24",
      "completion_date": "2030-04-19",
      "has_results": false,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-05-22T05:37:19.859Z",
      "location_count": 14,
      "location_summary": "Birmingham, Alabama • Orange, California • Washington D.C., District of Columbia + 11 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Orange",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06439082"
    },
    {
      "nct_id": "NCT00277849",
      "title": "Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hemoglobin Mutations",
        "Erythrocyte Variants"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 130,
      "start_date": "2006-01-11",
      "completion_date": "2010-07-20",
      "has_results": false,
      "last_update_posted_date": "2017-07-02",
      "last_synced_at": "2026-05-22T05:37:19.859Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00277849"
    },
    {
      "nct_id": "NCT03814746",
      "title": "Study of Two Doses of Crizanlizumab Versus Placebo in Adolescent and Adult Sickle Cell Disease Patients",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease (SCD)"
      ],
      "interventions": [
        {
          "name": "Crizanlizumab (SEG101)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "12 Years to 100 Years"
      },
      "enrollment_count": 255,
      "start_date": "2019-07-26",
      "completion_date": "2026-11-23",
      "has_results": true,
      "last_update_posted_date": "2026-04-21",
      "last_synced_at": "2026-05-22T05:37:19.859Z",
      "location_count": 5,
      "location_summary": "Atlanta, Georgia • Boston, Massachusetts • Charlotte, North Carolina + 2 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        },
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03814746"
    },
    {
      "nct_id": "NCT04935879",
      "title": "A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Pain Episode in Sickle Cell Disease",
        "Vaso-occlusive Crisis"
      ],
      "interventions": [
        {
          "name": "Inclacumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 241,
      "start_date": "2021-10-04",
      "completion_date": "2024-06-06",
      "has_results": true,
      "last_update_posted_date": "2025-12-02",
      "last_synced_at": "2026-05-22T05:37:19.859Z",
      "location_count": 22,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04935879"
    },
    {
      "nct_id": "NCT05348915",
      "title": "A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Crisis",
        "Vaso-occlusive Pain Episode in Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Inclacumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 242,
      "start_date": "2022-03-29",
      "completion_date": "2025-11-07",
      "has_results": false,
      "last_update_posted_date": "2025-12-17",
      "last_synced_at": "2026-05-22T05:37:19.859Z",
      "location_count": 18,
      "location_summary": "Mobile, Alabama • Little Rock, Arkansas • Orange, California + 7 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Orange",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05348915"
    },
    {
      "nct_id": "NCT05735717",
      "title": "MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Hematologic Malignancy",
        "Acute Leukemia",
        "Remission",
        "Acute Myeloid Leukemia",
        "Acute Lymphoblastic Leukemia",
        "AML",
        "TP53",
        "Intrachromosomal Amplification of Chromosome 21",
        "Cytogenetic Abnormality",
        "CNS Leukemia",
        "Minimal Residual Disease",
        "Myelodysplasia",
        "Juvenile Myelomonocytic Leukemia",
        "Somatic Mutation",
        "PTPN11 Gene Mutation",
        "N-RAS Gene Amplification",
        "Neurofibromatosis 1",
        "NF1 Mutation",
        "CBL Gene Mutation",
        "Monosomy 7",
        "Chromosome Abnormality",
        "Fetal Hemoglobin",
        "Lymphoblastic Lymphoma",
        "High Grade Non-Hodgkin's Lymphoma, Adult"
      ],
      "interventions": [
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Busulfan",
          "type": "DRUG"
        },
        {
          "name": "Melphalan",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Levetiracetam",
          "type": "DRUG"
        },
        {
          "name": "Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "Up to 60 Years"
      },
      "enrollment_count": 70,
      "start_date": "2023-05-11",
      "completion_date": "2030-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-06",
      "last_synced_at": "2026-05-22T05:37:19.859Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05735717"
    },
    {
      "nct_id": "NCT04927247",
      "title": "A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Sickle Cell Disease",
        "Vaso-occlusive Crisis",
        "Vaso-occlusive Pain Episode in Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Inclacumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "12 Years and older"
      },
      "enrollment_count": 72,
      "start_date": "2021-12-09",
      "completion_date": "2023-11-24",
      "has_results": true,
      "last_update_posted_date": "2024-12-11",
      "last_synced_at": "2026-05-22T05:37:19.859Z",
      "location_count": 17,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04927247"
    }
  ]
}